First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion
10.3779/j.issn.1009-3419.2024.102.11
- VernacularTitle:甲磺酸伏美替尼一线治疗1例EGFR 20号外显子插入突变肺腺癌患者
- Author:
LI ZHENGGUO
1
;
WEI TING
;
ZENG DUO
;
ZHAO LI
;
ZHANG JIANTING
;
CHEN LAIXIU
Author Information
1. 733000 武威,甘肃省武威肿瘤医院呼吸内科
- Keywords:
Lung neoplasms;
Furmonertinib mesylate;
Epidermal growth factor receptor;
Exon 20 insertion mutation
- From:
Chinese Journal of Lung Cancer
2024;27(3):241-244
- CountryChina
- Language:Chinese
-
Abstract:
With the continuous innovation of genomics,proteomics and molecular biological detection technol-ogy,the treatment of non-small cell lung cancer(NSCLC)has changed from traditional chemotherapy to immunotherapy and targeted therapy.Among them,molecular tumor markers targeting tyrosine kinase pathways play more important roles in clinical practice.For advanced NSCLC patients with positive epidermal growth factor receptor(EGFR)mutations,there are many first-line drugs on the market and they could bring significant efficacy,thus completely subverting the treatment pattern of advanced NSCLC.Common mutations of EGFR in Chinese patients are located on exons 19,20 and 21,of which exons 19 and 21 mutations are the more common types.Besides,there is also a subtype of EGFR mutations,known as EGFR 20 exon insertion(EGFR 20ins)mutation.The authors summarized the treatment of a lung adenocarcinoma patient with EGFR 20ins mutation accepting Furmonertinib mesylate,in order to provide effective references for clinical diagnosis and treatment.
